TNFRSF17 and plasma cell myeloma: Ciltacabtagene autoleucel is the most recent B-cell maturation antigen (BCMA) directed CAR-T cell therapy approved for adults with relapsed and/or refractory multiple myeloma (r/r MM) (26).